December 2025 in “Frontiers in Nutrition” Collagen supplements may improve skin, joints, and recovery, especially with added nutrients.
December 2025 in “Yemeni Journal of Agriculture & Veterinary Sciences” Many sheep and goats in Sana’a, Yemen, lack essential minerals and need supplements for better health.
November 2025 in “Biological Trace Element Research” Hair mineral analysis doesn't reliably show blood mineral levels but may help track long-term mineral trends.
October 2025 in “Scientific Reports” Serenoa repens extract shows promise as a natural treatment for prostate cancer.
May 2025 in “The Journal of Rheumatology” A woman with skin and joint issues progressed from one type of lupus to another, highlighting the need to recognize complex conditions.
May 2025 in “The Journal of Rheumatology” Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.
May 2025 in “The Journal of Rheumatology” Trans-esophageal echocardiography is crucial for accurately diagnosing heart issues in lupus patients.
May 2025 in “The Journal of Rheumatology” Chronic granulomatous disease may be linked to developing systemic lupus erythematosus.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
May 2025 in “The Journal of Rheumatology” Proactive physical therapy improved mobility, reduced fatigue, and pain in lupus patients.
May 2025 in “The Journal of Rheumatology” Mixed Connective Tissue Disease can develop from overlapping symptoms of several autoimmune diseases, making diagnosis complex.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
May 2025 in “The Journal of Rheumatology” Early recognition and management of gastrointestinal tuberculosis in lupus patients are crucial to prevent complications.
May 2025 in “The Journal of Rheumatology” Catatonia can be a rare sign of lupus, needing careful diagnosis and treatment.
May 2025 in “The Journal of Rheumatology” Purpura fulminans can signal underlying autoimmune disorders, not just infections.
May 2025 in “The Journal of Rheumatology” Lupus patients in Ghana face healthcare challenges, and the Oyemam Autoimmune Foundation is working to improve awareness and support.
May 2025 in “The Journal of Rheumatology” Bullous lupus can cause severe esophageal issues but responds well to corticosteroids and azathioprine.
May 2025 in “The Journal of Rheumatology” Correct diagnosis is crucial for treating overlapping conditions like NMOSD and SLE effectively.
May 2025 in “The Journal of Rheumatology” Middle-aged women with dilated cardiomyopathy should be screened for antiphospholipid syndrome.
May 2025 in “The Journal of Rheumatology” Early recognition and a team approach are crucial for managing diffuse alveolar hemorrhage in antiphospholipid syndrome.
May 2025 in “The Journal of Rheumatology” Antiphospholipid syndrome can severely damage adrenal glands, requiring early diagnosis and treatment.
May 2025 in “The Journal of Rheumatology” SLE can cause unusual gastrointestinal symptoms, and immunosuppressive therapy can be effective.
February 2025 in “Clinical Cosmetic and Investigational Dermatology” Higher fasting insulin levels increase the risk of androgenetic alopecia.
Hibiscus rosa-sinensis can naturally help heal skin inflammation.
The mesenchymal stem cell secretome may effectively treat various diseases as an alternative to traditional stem cell therapies.
May 2024 in “KIU journal of health science” Kolaviron and quercetin may help treat prostate issues.
Sunekos® effectively improves labia majora appearance and is well-tolerated.
April 2024 in “bioRxiv (Cold Spring Harbor Laboratory)” Removing Sprouty genes in mice causes various hormone-related issues but does not increase cancer risk by one year of age.
Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.